Fig. 4: Variables associated with clinical benefit to immune checkpoint blockade across both relapsed small cell lung cancer cohorts.
From: Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
Association between clinical benefit to ICB and expression of a transcriptional subtype genes, b EZH2 and ssGSEA NE differentiation and immune signature scores, c MYC family members (MYC, MYCN and MYCL) and d established Notch signaling target genes. Statistical significance was tested with a two-tailed Mann–Whitney U test. Boxplots represent the median, 25th and 75th percentiles and the vertical bars span the 5th to the 95th percentiles. Source data are provided as a Source Data file.
